Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.46 |
| ▸ | SYK | P43405 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 8/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | WEE1 | P30291 | 1/20 | 0.41 |
| ▸ | PLK2 | Q9NYY3 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | WNK2 | Q9Y3S1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616799 | 0.86 | CDC7 (0.50) | ULK1SYKEGFRIGF1RWEE1 | |
| SCHEMBL13616147 | 0.83 | JAK1 (0.43) | PLK1 | |
| SCHEMBL13616093 | 0.77 | RPS6KA6 (0.59) | FGFR3 | |
| SCHEMBL13616167 | 0.76 | CDK2 (0.57) | PLK2PLK1 | |
| SCHEMBL11976974 | 0.75 | RPS6KA6 (0.59) | EGFRWEE1KITFGFR3FLT3 | |
| SCHEMBL13616293 | 0.74 | CDK4 (0.60) | EGFRWEE1KITFGFR3FLT3 | |
| SCHEMBL1675717 | 0.74 | PLK1 (0.61) | ULK1SYKEGFRPLK2LCK | |
| SCHEMBL12631916 | 0.73 | AURKA (0.55) | ULK1SYKIGF1RPLK2LCK | |
| SCHEMBL4783750 | 0.73 | PLK1 (0.52) | ULK1SYKEGFRIGF1RPLK2 | |
| SCHEMBL11977085 | 0.72 | EGFR (0.48) | ULK1SYKEGFRIGF1RPLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | ULK1 467/4885SYK 1001/4885EGFR 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.